18 Patients recruited in 6 months to WHITE Platform Orthopaedic Trials Duality and LIT

December 18, 2023

Congratulations to Belfast based Orthopaedics Research coordinator Sharon Marks who has been recruiting well to both the DUALITY and LIT studies.

Sharon has only been in post for 6 months but this hasn’t stopped her from recruiting 9 patients to both NIHR studies, 18 in total.

WHITE PLATFORM 12: DUALITY: Dual mobility (DM) versus standard articulation total hip replacement (THR) in the treatment of older adults with a hip fracture. Aims to find out what the clinical and cost effectiveness of dual mobility versus standard articulation total hip replacement in the treatment of adults aged 65 years and over with an acute, displaced intracapsular hip fracture. Find our more here.

WHiTE10 – LIT: Lidocaine Intravenous Trial (LIT). Aims to investigate the use of a drug called ‘lidocaine’ to see if it reduces the risk of delirium during surgery for a hip fracture. Find our more here.

Both studies falls under the WHITE Platform framework and are open to all patients aged over 60 years with a hip fracture, apart from the very small number of patients who have an allergy or another reason not to have lidocaine. Eligible patients will be approached about the individual studies before their treatment where possible. Patients who are unable to consent for themselves may take part in the trial with the agreement of their relatives or an independent doctor, who will be known as legal representatives.

Keep up the amazing work Sharon and the Orthopaedics teams in RVH and MPH.

By Emma Byrne